The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2528-2531

  Lockhart, Shawn R ^a   Fothergill, Annette W ^b   Iqbal, Naureen ^a   Bolden, Carol B ^a   Grossman, Nina T ^a   Garvey, Edward P ^c   Brand, Stephen R ^c   Hoekstra, William J ^c   Schotzinger, Robert J ^c   Ottinger, Elizabeth ^d   Patterson, Thomas F ^b,e   Wiederhold, Nathan P ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Viamet Pharmaceuticals   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; UNCLASSIFIED DRUG; VT 1129; FUNGAL PROTEIN; NEW DRUG; PYRIDINE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TETRAZOLE DERIVATIVE; VT-1129;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; FUNGUS ISOLATION; GENOTYPE; HUMAN; IN VITRO STUDY; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

14-ALPHA DEMETHYLASE INHIBITORS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; DRUGS, INVESTIGATIONAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION; GENOTYPE; MICROBIAL SENSITIVITY TESTS; PYRIDINES; STEROL 14-DEMETHYLASE; TETRAZOLES;

EID: 84963717381     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02770-15     Document Type: Article

References (18)

1. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by The Infectious Diseases Society of America. Clin Infect Dis 50:291-322. http://dx.doi.org/10.1086/649858.
2. Chayakulkeeree M, Perfect JR. 2006. Cryptococcosis. Infect Dis Clin North Am 20:507-544, v-vi. http://dx.doi.org/10.1016/j.idc.2006.07.001.
3. Li SS, Mody CH. 2010. Cryptococcus. Proc Am Thorac Soc 7:186-196. http://dx.doi.org/10.1513/pats.200907-063AL.
4. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530. http://dx.doi.org/10.1097/QAD.0b013e328322ffac.
5. Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. 2014. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett 24:3455-3458. http://dx.doi.org/10.1016/j.bmcl.2014.05.068.
6. Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL. 2014. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother 58:7121-7127. http://dx.doi.org/10.1128/AAC.03707-14.
7. Garvey EP, Hoekstra WJ, Schotzinger RJ, Fothergill AW, Wiederhold NP, Warrilow AGS, Kelly DE, Kelly SL. 2015. VT-1129 binds potently and selectively to recombinant cryptococcal CYP51 consistent with its potent in vitro anti-cryptococcal activity, poster M-848. Abstr 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA.
8. Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR. 2011. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother 55:2606-2611. http://dx.doi.org/10.1128/AAC.00048-11.
9. Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris JR. 2012. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 73:144-148. http://dx.doi.org/10.1016/j.diagmicrobio.2012.02.018.
10. Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR. 2010. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 48:539-544. http://dx.doi.org/10.1128/JCM.01505-09.
11. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-Chung J. 2009. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47:561-570. http://dx.doi.org/10.1080/13693780902953886.
12. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA
13. Thompson GR, III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53:309-311. http://dx.doi.org/10.1128/AAC.01216-08.
14. Yildiran ST, Fothergill AW, Sutton DA, Rinaldi MG. 2002. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 45:378-383. http://dx.doi.org/10.1046/j.1439-0507.2002.00765.x.
15. Trilles L, Fernandez-Torres B, dos Santos Lazera M, Wanke B, Guarro J. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 42:4815-4817. http://dx.doi.org/10.1128/JCM.42.10.4815-4817.2004.
16. Thompson GR, III, Fothergill AW, Wiederhold NP, Vallor AC, Wickes BL, Patterson TF. 2008. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 52:2959-2961. http://dx.doi.org/10.1128/AAC.00646-08.
17. Guinea J, Hagen F, Pelaez T, Boekhout T, Tahoune H, Torres-Narbona M, Bouza E. 2010. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol 48:942-948. http://dx.doi.org/10.3109/13693781003690067.
18. Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF. 2010. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 54:5139-5145. http://dx.doi.org/10.1128/AAC.00746-10.